Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
52 Obesity Trials near Philadelphia, PA
Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Tirzepatide for Obesity
Philadelphia, PennsylvaniaThis trial is testing tirzepatide, a medication that helps control blood sugar and reduce appetite, to see if it can lower health problems and death rates in adults who are very overweight. Tirzepatide was developed by Eli Lilly to improve blood sugar control in adults with type 2 diabetes.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
15374 Participants Needed
CagriSema vs. Tirzepatide for Weight Loss in Obesity
Philadelphia, PennsylvaniaThis trial tests if a new combination of two drugs, given regularly, helps people lose weight better than another treatment. It targets individuals needing to lower their body weight by helping them feel less hungry and manage their weight. Two different drugs are being investigated as options for weight management.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
809 Participants Needed
Setmelanotide for Hypothalamic Obesity
Philadelphia, PennsylvaniaThis trial tests if Setmelanotide, an injection, can help reduce weight and hunger in patients aged 4 and older with acquired Hypothalamic Obesity. The medication works by targeting brain pathways that control hunger and energy use. Setmelanotide has been approved for treating obesity in rare genetic conditions and is being developed for other obesity-related disorders.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4+
Sex:All
120 Participants Needed
CagriSema for Obesity
Philadelphia, PennsylvaniaThis trial tests how well different treatments help people with excess body weight lose weight. Participants will receive one of four treatments through regular injections. The study will last over a year, followed by a period to observe long-term effects.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
3400 Participants Needed
Setmelanotide for Obesity
Philadelphia, PennsylvaniaThe protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:
* POMC or PCSK1 (Sub-study 035a)
* LEPR (Sub-study 035b)
* SRC1 (Sub-study 035c)
* SH2B1 (Sub-study 035d)
The objectives and endpoints are identical for these sub-studies.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 65
Sex:All
400 Participants Needed
Digital Intervention for Binge Eating
Philadelphia, PennsylvaniaThe proposed study is an open label, non randomized, waitlist controlled single group feasibility study of the feasibility and usability of a digital intervention (called ChangeBite) to be used by individuals with obesity and comorbid binge eating behavior. The proposed research will include approximately 30 participants. Participants will be recruited for this single group pilot trial using online advertising to attend a virtual screening session. Screened participants willing and eligible to participate, will receive informed consent and formally start ChangeBite. Participants will be instructed to engage with ChangeBite and attend follow up assessments on scheduled video calls. Feasibility and acceptability of implementation will be assessed by collecting data on recruitment, retention, usability and satisfaction. The research team will also collect assessment data from participants on feasibility, and usability. In addition to self report scales, semi-structured interviews will be completed with a trained research team member via video call and will be partially recorded. Assessments will be done at baseline, 12 weeks, and 24 weeks. Participants' app use frequency and duration will be tracked using software analytics. Participants' body weight will be captured weekly using a timestamped picture of their weight as it appears on their scale and Body Mass Index will be calculated with these data points.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Eating Disorder Treatment, Weight Loss Treatment, Severe Psychopathology, Pregnancy, Others
Must Not Be Taking:Antipsychotics
30 Participants Needed
NNC0519-0130 for Obesity
Philadelphia, PennsylvaniaThis study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
355 Participants Needed
Caloric Restriction + Activity for Acute Lymphoblastic Leukemia
Philadelphia, PennsylvaniaThis trial tests if a personalized diet and exercise plan can help older children, adolescents, and young adults with high-risk B-cell Acute Lymphoblastic Leukemia respond better to chemotherapy. The plan aims to reduce body fat, which is linked to treatment resistance, and limit fat gain during chemotherapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:10 - 25
Sex:All
Key Eligibility Criteria
Disqualifiers:Underweight, Down Syndrome, Previous Malignancy, Others
Must Be Taking:Vincristine, Glucocorticoid, Pegaspargase, Daunorubicin
240 Participants Needed
AI-Optimized Weight Loss Treatment for Obesity
Philadelphia, PennsylvaniaThis trial is testing a smart computer program that helps people lose weight by giving them personalized advice. It tracks their progress and provides the best support based on individual responses. The goal is to see if this method is more effective and cheaper than traditional weight loss coaching.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 70
Sex:All
336 Participants Needed
Protein Intake for Obesity
Philadelphia, PennsylvaniaThis study will examine a potential relationship between family history of obesity, that is whether people with at least one parent who had obesity in adulthood compared to people with two parents who did not have obesity in adulthood, and the ability of protein intake to curb further intake of food.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 35
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychiatric, Neurological, Anorexia, Bulimia, Others
Must Not Be Taking:Anti-seizure, Antidepressants, Antipsychotics
80 Participants Needed
Acceptance-Based Treatment for Adolescent Obesity
Philadelphia, PennsylvaniaThe goal of this clinical trial is to learn about cardiovascular disease risk among adolescent girls with overweight/obesity. The main questions this trial aims to answer are:
1. Does an acceptance-based healthy lifestyle intervention demonstrate more weight loss than a health education intervention?
2. Does an acceptance-based healthy lifestyle intervention show more improvements in participants' physiological, health-related, and psychological factors compared to a health education intervention?
Participants in this trial will:
1. Engage in treatment for 6-months, comprising of a mixture of in-person and remote group sessions, occurring at Drexel University or over a video-conferencing platform.
2. Complete various assessments. These include self-reported questionnaires, measures of weight, height, body composition, blood pressure, and blood lipids, and wearing of smart watches to measure sleep and physical activity.
Researchers will compare the acceptance-based and health education intervention groups to see if the acceptance-based treatment will indeed be effective in improving participants' health outcomes.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 19
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Cancer, Cardiovascular Disease, Others
Must Not Be Taking:Appetite Suppressants
148 Participants Needed
Mobile Health Program for Childhood Obesity
Philadelphia, PennsylvaniaThe goal of this clinical trial is to compare the effectiveness of a mobile health intervention in adolescents (14-17 years) with overweight or obesity.
The main question\[s\] it aims to answer are: 1) is a digital-based diet quality intervention for adolescents with overweight or obesity feasible and 2) is there preliminary effectiveness in improving diet quality?
Participants will:
1. Complete three-day 24-hour dietary recalls
2. Collect urine samples
3. Wear a continuous glucose monitor, sleep tracker, and physical activity tracker
Researchers will compare control and intervention groups to see if diet quality and meal timing traits improve as assessed by 24-hour dietary recalls, a novel urine biomarker, and continuous glucose monitoring (CGM).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Eating Disorders, Diabetes, Celiac's, Others
Must Not Be Taking:Weight Loss Drugs
210 Participants Needed
Weight Loss Maintenance for Obesity
Philadelphia, PennsylvaniaThe goal of this clinical trial is to determine the physiological basis for the differences in weight regain among adults (25-59 years old) with obesity following participation in a behavioral weight loss program. Eligible participants will undergo a baseline evaluation after which they will enter an up to 20 week behavioral weight loss program with the goal of losing at least 7 percent of their baseline weight within 37 weeks. Participants who meet the weight loss goal will be asked to remain weight stable for 2 weeks after which they will undergo a clinical examination. They will then be observed for 1 year during which they will undergo 2 additional clinical examinations, one 4 months after completing the weight loss program, and the other 12 months after completing the weight loss program.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:25 - 59
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Cardiovascular Disease, Cancer, Others
Must Not Be Taking:Anticoagulants, Antiretrovirals, Appetite Suppressants, Others
205 Participants Needed
Mobile Health App for Sleep Promotion and Obesity Prevention in Children
Philadelphia, PennsylvaniaThe overall objective of this application is to develop a mobile health platform for the pediatric care setting to promote longer sleep duration for childhood obesity prevention.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 12
Sex:All
Key Eligibility Criteria
Disqualifiers:Chronic Disease, Behavioral Health, Others
Must Not Be Taking:Steroids, Hormones, Others
5000 Participants Needed
Gamification for Obesity
Philadelphia, PennsylvaniaThis trial uses game-like elements to make exercise more fun for obese Veterans with high blood pressure. By encouraging competition or teamwork, it aims to help them be more active and healthier.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18+
Sex:All
459 Participants Needed
Decision-Making Skills for Adolescent Obesity
Philadelphia, PennsylvaniaThis trial involves an online group program aimed at helping teenagers aged 14-18 with overweight or obesity lose weight. The program focuses on improving food choices by teaching better decision-making skills, especially for those who struggle with loss-of-control eating.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:14 - 18
Sex:All
63 Participants Needed
Responsive Neurostimulation for Binge Eating Disorder
Philadelphia, PennsylvaniaThe primary objective of this trial is to assess device function and safety, with secondary objectives including the feasibility.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Severe Depression, Drug Abuse, Others
Must Be Taking:GLP-1 Agonists
6 Participants Needed
Dissonance-Based Obesity Prevention + Response and Attention Training for Obesity
Philadelphia, PennsylvaniaThis project seeks to improve the effectiveness of a novel dissonance-based obesity prevention program that has reduced future BMI gain and overweight/obesity onset by (a) experimentally testing whether implementing it in single- versus mixed-sex groups, which should increase dissonance-induction that contributes to weight gain prevention effects, and (b) experimentally testing whether adding food response and attention training, which theoretically reduces valuation of and attention for high-calorie foods, increases weight gain prevention effects. This randomized trial would be the first to experimentally manipulate these two factors in an effort to produce superior weight gain prevention effects. A brief effective obesity prevention program that can be easily, inexpensively, and broadly implemented to late adolescents at risk for excess weight gain, as has been the case with another dissonance-based prevention program, could markedly reduce the prevalence of obesity and associated morbidity and mortality.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:17 - 20
Sex:All
406 Participants Needed
Lifestyle and Sleep Intervention for Obesity
Philadelphia, PennsylvaniaThis study is being performed to understand the effects of a lifestyle modification and sleep intervention on weight loss outcomes in adolescence. The main question the study aims to answer is:
- What are the initial effects of a lifestyle modification and sleep intervention, including effects on weight, eating behaviors and dietary intake, and sleep?
Participants will:
* Participate in remote, group-based, weekly weight loss and sleep coaching for 16 weeks.
* Complete study assessments at baseline (pre-intervention), mid-intervention, and post-intervention.
* Complete daily sleep diaries for three 7-day periods at each assessment point.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:14 - 18
Sex:All
50 Participants Needed
Healthy Foods Program for Diabetes and Obesity
Philadelphia, PennsylvaniaThe goal of this interventional study is to test ways to improve the effectiveness of a healthy foods prescription program in increasing the purchase of healthy foods for patients who have both obesity (BMI \>or= 30) and diabetes (last A1C\>8 in the 90 days from data pull). The main questions it aims to answer are:
Aim 1: Examine feasibility and engagement among participants by assessing percent enrollment among those identified as eligible, rates of Instacart platform use, amount of the subsidy used each week, and amounts of healthy foods ordered.
Aim 2: Examine strategies to optimize the user experience of trial participation, including communication strategies and on-boarding, to increase uptake and engagement in this and subsequent studies.
Usual Care (Control): Participants in the usual care arm will not receive weekly subsidies on Instacart, and they will not receive any modifications to the virtual storefront on Instacart. They will have access to the standard Instacart platform and Instacart + memberships with $5 per week to cover service and delivery fees and delivery tips for 3 months.
Intervention Arms: The four treatment groups will also each receive a $160 subsidy per month for 3 months to be used on produce (fruits and vegetables).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:30 - 70
Sex:All
224 Participants Needed
Long-Term Setmelanotide for Obesity
Philadelphia, PennsylvaniaThis is a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in patients who have completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:2 - 65
Sex:All
300 Participants Needed
Electronic Health Record Prompts for Childhood Obesity
Philadelphia, PennsylvaniaThe purpose of this study is to evaluate the dissemination and implementation of electronic health record-based clinical decision support tools for the management of pediatric overweight and obesity in primary care.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:2+
Sex:All
240772 Participants Needed
Digital Data Sharing for Weight Loss
Philadelphia, PennsylvaniaAdults attempting weight loss through lifestyle modification (LM) typically find maintenance of behavior change difficult. Outcomes might be improved if participants are provided with sustained sources of accountability and support and ongoing opportunities to reflect with others on goal progress. This study proposes that sharing digital data with other parties has the potential to improve long-term weight loss. The proposed study will enroll adults ("index participants") (N = 320) with overweight/obesity in a 24-month LM program and instruct them to use digital tools for self-monitoring of weight, physical activity, and eating on a daily basis.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Cancer, Type I Diabetes, Psychosis, Others
Must Not Be Taking:Insulin, Weight-loss Drugs
320 Participants Needed
Behavioral Intervention for Childhood Obesity
Philadelphia, PennsylvaniaA genetic risk for obesity does not always translate to the development of obesity among children, which points to the presence of risk-modifying factors that likely relate to energy balance behaviors as key behavioral drivers. Using an integrated approach to comprehensively examine the interplay between genotype and phenotype, this study will systematically assess the extent to which energy balance behaviors, alone or in combination, in conjunction with family-level influences can modify behavioral and genetic predispositions to childhood obesity in a high-risk sample of predominantly minority children from low-resource backgrounds. Identifying protective factors that may mitigate the impact of obesity risk on weight and adiposity outcomes is critical for moving the prevention of childhood obesity into a new direction.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:5 - 7
Sex:All
Key Eligibility Criteria
Disqualifiers:Serious Medical, Psychiatric, Food Allergies, Others
Must Not Be Taking:Weight Medications
158 Participants Needed
Low GI Diet for Leukemia
Philadelphia, PennsylvaniaThe study aims to determine the feasibility of a 6-month low glycemic dietary intervention in children and adolescents undergoing treatment for acute lymphoblastic leukemia.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:5 - 21
Sex:All
88 Participants Needed
Phentermine/Topiramate for Hypothalamic Obesity
Philadelphia, PennsylvaniaHypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and later experience excess mortality related to cardiometabolic disease. In this pilot trial, our objective is to gather key preliminary data about phentermine/topiramate (Ph/T) that is FDA-approved for "common" obesity but has never been tested in HO. The subset of individuals with HO who experience hyperphagia or excess daytime sleepiness may benefit from the Ph/T-induced decrease in appetite and increase in alertness.
Preliminary assessments of safety, adverse events, dosing (Aim 1), as well as of efficacy (% BMI loss, Aim 2) will be made in a 28-week parallel-arm double-blinded Phase 2 placebo-controlled clinical trial in 12-28-year-old individuals with HO.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 28
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Conditions, Diabetes, Liver Disease, Others
Must Be Taking:Pituitary Replacements, Appetite-modulating
24 Participants Needed
Training Program for Obesity Counseling
Philadelphia, PennsylvaniaThe goal of this study is to addresses the lack of weight management training physicians receive during their residency training. The main questions it aims to answer are:
* How affective is the MRWeight curriculum at increasing medical residents weight management counseling (WMC) skills.
* Evaluate residents' adoption of WMC skills in encounters with their patients
* what would be the best way to get residents to adopt the WMC skills Residents in the comparison group will receive a course on obesity and weight management. The residents in the intervention group will have to attend 2 informational sessions and will receive 6 email modules on WMC. Both groups will also take part in 3 assessments over the course of 18 months to see which group has better WMC skills.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
630 Participants Needed
Ultra-Processed Foods' Impact on Obesity
Philadelphia, PennsylvaniaThe changing food environment, with increasingly abundant ultra-processed food (UPF) options, may directly contribute to rising rates of obesity, though it is unknown which ingredients in UPF elevate their reinforcing nature in a way that may lead to overconsumption. The proposed study is the first to systematically examine differences in the rewarding characteristics of and physiological and metabolic responses to UPFs that are high in fat, refined carbohydrates (like sugar), or both. Understanding the biobehavioral underpinnings that enhance the reinforcing potential of ingredients in UPF (e.g., fat vs. refined carbohydrates) can inform novel intervention targets for the treatment of overeating and obesity.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Hypertension, Cardiovascular Events, Others
Must Not Be Taking:Metformin, Liraglutide
50 Participants Needed
Antenatal Obesity Treatment for Pregnancy-Related Obesity
Philadelphia, PennsylvaniaThe purpose of this study is to determine the effect of an antenatal obesity treatment on gestational weight gain when integrated into Philadelphia WIC.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
416 Participants Needed
Gamified Weight Loss Program for Obesity
Philadelphia, PennsylvaniaMen in the United States have an exceptionally high prevalence of overweight and obesity, i.e., 71.3%, and 42% of men are currently attempting weight loss. However, men are dramatically underrepresented in weight loss programs. Attempts to modestly adapt standard weight loss programs have seen only minimal success. Mobile applications (mHealth apps) have attractive features, but have low male enrollment and poor efficacy as conventionally delivered. A gamified mHealth program offers the possibility of engaging men and enhancing efficacy given that (1) video gaming is highly appealing to men; (2) gamification features (e.g., digital rewards for attaining "streaks" and milestones, competition) are known enhance enjoyment and motivation and facilitate desired behaviors; and (3) "neurotraining" video games featuring repetitive action mechanics, adaptive difficulty, and feedback can train inhibitory control, a basic brain capacity to inhibit intrinsically-generated approach responses that is strongly linked to body mass and the consumption of high-calorie foods. This project evaluates long-term engagement and outcomes of a professionally-designed, game-based weight loss program. As such, 228 overweight men will be randomized to: (1) a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining, or (2) a fully-gamified version of this same program, comprised of a behavior change program featuring team-based competition, digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game. Aims include evaluating the efficacy of the gamified program in terms of weight loss, diet and physical activity at 12 months, as well as evaluating hypothesized mediators (inhibitory control and engagement), (enjoyment and compliance) and moderators (baseline frequency of video game play and implicit preferences for Inhibitory Control Training-targeted foods).
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Cancer, Type I Diabetes, Renal Failure, Others
228 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Obesity clinical trials in Philadelphia, PA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Obesity clinical trials in Philadelphia, PA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Obesity trials in Philadelphia, PA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Philadelphia, PA for Obesity is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Philadelphia, PA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Obesity medical study in Philadelphia, PA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Obesity clinical trials in Philadelphia, PA ?
Most recently, we added Gamification for Hospital Mobility Improvement, Tirzepatide for Type 1 Diabetes and Obesity and Behavioral Sleep Intervention for Childhood Obesity to the Power online platform.